drugset / Trial / NCT00401375

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

NCT00401375 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of MNTX in participants who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen.

Timeline

Start
2006-10-31
Primary completion
2008-02-29
Completion
2008-02-29

Outcome

Missed primary endpoint

paper The primary and secondary efficacy outcomes (time to discharge eligibility, time to hospital discharge, and clinically meaningful events of nausea and vomiting following segmental colectomy) did not differ significantly between patients treated with either a dose of methylnaltrexone or with placebo. PMID 21471758 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified 12 mg Intravenous
Subject Methylnaltrexone Other / unclassified 24 mg Intravenous

Indications